Prophylactic and therapeutic itaconate treatment alleviates COVID-19-associated lung injury
Year: 2025
Type: article
Abstract: Although itaconate (ITA) demonstrates anti-inflammatory and antimicrobial properties as an immunomodulatory metabolite, the therapeutic or prophylactic potential of ITA in coronavirus disease 2019 (COVID-19) remains underexplored. This study investigates the therapeutic and prophylactic potential of ITA against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced acute lung injury (ALI) in hamster models. Metabolomic analyses revealed that intranasal administration of a dNS1-RBD vaccine (a live-attenuated, cold-adapted influenza virus-based vaccine deficient in nonstructural protein 1 (NS1) and expressing the SARS-CoV-2 receptor binding domain (RBD)) upregulated ITA levels, prompting further exploration of its immunomodulatory role. Both prophylactic and therapeutic ITA treatments significantly mitigated weight loss, improved lung pathology. Transcriptional profiling demonstrated that ITA downregulated immune activation pathways while enhancing fatty acid β-oxidation (FAO)-related genes, correlating with reduced pro-inflammatory cytokine/chemokine release. Metabolomic analysis identified enriched arginine-proline metabolism pathways in ITA-treated groups. Single-cell RNA sequencing of human bronchoalveolar lavage fluid (BALF) highlighted macrophage clusters enriched in peroxisome proliferator-activated receptor (PPAR) signaling and FAO, which were deficient in severe COVID-19 patients. ITA treatment preserved transcriptional networks involving PPARG , RARA , BHLHE41 , TCF7L2 , and ESRRA , linked to macrophage self-renewal and metabolic homeostasis. These findings underscore ITA’s role in modulating immunometabolic responses, particularly through FAO-driven macrophage reprogramming, to attenuate SARS-CoV-2-induced lung damage. This study provides insights into host-directed therapies targeting metabolic reprogramming to mitigate COVID-19 severity.
Source: hLife
Authors: Yao Jiang, Peida Yang, Bo Yao, Liang Zhang, Man Yang, Yiyi Chen, Lunzhi Yuan, Junyu Chen, Jinhang He, Xing Lei, Feng Chen, Mingxi Yue, Siping Yan, Tong Cheng, Yixin Chen, Quan Yuan, Jun Zhang, Shuhai Lin, Tianying Zhang, Ningshao Xia
Institution: Xiamen University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,300
Funders: National Natural Science Foundation of China, National Health and Family Planning Commission of the People's Republic of China, Natural Science Foundation of Beijing Municipality, Beijing Municipal Science and Technology Commission, National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities
OpenAlex ID: W4411487585
